# A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

> **NCT04487574** · PHASE3 · COMPLETED · sponsor: **RSV Therapeutics LLC** · enrollment: 118 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** XC221
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04487574
- **Lead sponsor:** RSV Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-25
- **Primary completion:** 2020-10-29
- **Final completion:** 2020-10-29
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04487574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04487574, "A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04487574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*